Nevirapine
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.2. Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
ATC codes: J05AG01
EMLc
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
ICD11 code: 1C62.Z
INN
Nevirapine
Medicine type
Chemical agent
List type
Core
Formulations
Oral > Liquid: 50 mg per 5 mL
Oral > Solid > dispersible tablet: 50 mg
Oral > Solid > tablet: 200 mg (EML)
EML status history
First added in 1999 (TRS 895)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 950)
Changed in 2015 (TRS 994)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Age restriction
> 6 weeks
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more about patents.
Wikipedia
Nevirapine
DrugBank
Nevirapine
Summary of evidence and Expert Committee recommendations
☐
The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an“optimal” paediatric formulation.